You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project
|
|---|---|
| Published in |
Cancer Prevention Research, December 2015
|
| DOI | 10.1158/1940-6207.capr-15-0126 |
| Pubmed ID | |
| Authors |
Jessica L Petrick, Vikrant V Sahasrabuddhe, Andrew T Chan, Michael C Alavanja, Laura E Beane-Freeman, Julie E Buring, Jie Chen, Dawn Q Chong, Neal D Freedman, Charles S Fuchs, John Michael Gaziano, Edward Giovannucci, Barry I Graubard, Albert R Hollenbeck, Lifang Hou, Eric J Jacobs, Lindsay Y King, Jill Koshiol, I-Min Lee, Martha S Linet, Julie R Palmer, Mark P Purdue, Lynn Rosenberg, Catherine Schairer, Howard D Sesso, Alice J Sigurdson, Jean Wactawski-Wende, Anne Zeleniuch-Jacquotte, Peter T Campbell, Katherine A McGlynn |
| Abstract |
Chronic inflammation plays a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), the two most common types of liver cancer. A number of prior experimental studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, may potentially protect against liver cancer. However, no observational study has examined the association between aspirin duration and dose or other over-the-counter non-aspirin NSAIDs, such as ibuprofen, and liver cancer incidence. Furthermore, the association between NSAID use and risk of ICC is unclear. As part of the Liver Cancer Pooling Project, we harmonized data on 1,084,133 individuals (HCC=679, ICC=225) from ten US-based prospective cohort studies. Cox proportional hazards regression models were used to evaluate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Current aspirin use, versus nonuse, was inversely associated with HCC (HR=0.68, 95% CI=0.57-0.81), which persisted when restricted to individuals not using non-aspirin NSAIDs and in a 5 and 10-year lag analysis. The association between aspirin use and HCC risk was stronger for users who reported daily use, longer duration use, and lower dosage. Ibuprofen use was not associated with HCC risk. Aspirin use was associated with a reduced ICC risk in men (HR=0.64, 95% CI=0.42-0.98) but not women (HR=1.34, 95% CI=0.89-2.01, pinteraction=0.01). The observed inverse association between aspirin use and liver cancer in our study, together with previous data, suggest the merit of future intervention studies of aspirin and other agents that affect chronic inflammatory pathways for HCC and possibly ICC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 5% |
| Unknown | 35 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 24% |
| Researcher | 8 | 22% |
| Lecturer | 2 | 5% |
| Other | 2 | 5% |
| Student > Postgraduate | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 14% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Immunology and Microbiology | 2 | 5% |
| Arts and Humanities | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 11 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2015.
All research outputs
#15,650,368
of 24,059,832 outputs
Outputs from Cancer Prevention Research
#983
of 1,408 outputs
Outputs of similar age
#220,933
of 395,718 outputs
Outputs of similar age from Cancer Prevention Research
#14
of 26 outputs
Altmetric has tracked 24,059,832 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,408 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.4. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,718 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.